Mease PJ, Helliwell PS, Hjuler KF, et al. - The efficacy and safety of brodalumab, an interleukin-17 receptor subunit A inhibitor, vs placebo, were investigated in patients with psoriatic arthritis (PsA). Two phase 3 studies (NCT02029495 and NCT02024646) were conducted including 962 adult patients with active PsA and inadequate response to, or intolerance to, conventional treatment and randomizing them 1:1:1 to receive subcutaneous brodalumab 140 mg or 210 mg or placebo at weeks 0, 1 and every 2 weeks up to 24 weeks. Outcomes revealed correlation of brodalumab with rapid and significant improvements in signs and symptoms of PsA vs placebo. Participants showed good tolerability towards brodalumab, with a safety profile consistent with other interleukin-17 inhibitors.